Glicisa-M 1 Forte Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by reducing hepatic glucose production and increasing peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The prolonged-release formulation ensures a sustained therapeutic effect, optimizing plasma drug levels and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glicisa-M 1 Forte is prescribed as an adjunct to diet and exercise to achieve better glycemic control in patients inadequately controlled on monotherapy or lifestyle modifications alone. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Common adverse effects include hypoglycemia, gastrointestinal disturbances, and, rarely, lactic acidosis. Patient adherence to prescribed dosing and lifestyle modifications is critical for optimal outcomes. This combination therapy offers a synergistic mechanism targeting multiple pathophysiological defects in type 2 diabetes.